July 4, 2023
ISOFOL PRESENTS CONCLUSIONS FROM
THE IN-DEPTH ANALYSIS OF THE AGENT STUDY
June 22, 2023
ISOFOL´S BOARD OF DIRECTORS APPOINTS
ROGER TELL AS ACTING CEO OF THE COMPANY
This website is intended for use by residents of Sweden only
About Isofol
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.
Upcoming Events
- November 10, 2023 - November 10, 2023
Interim report July-September 2023 - February 20, 2024 - February 20, 2024
Year-End-Report
Media – Lates pressreleases
Isofol Medical AB (publ) publishes interim report, January–June 2023
GOTHENBURG, Sweden, August 22, 2023 – Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announced today that the company’s interim report for January–June 2023 is…
Isofol presents conclusions from the in-depth analysis of the AGENT study
Gothenburg, Sweden, July 4, 2023 – Isofol Medical AB (publ) today presents the conclusions from the company’s in-depth analysis of data from the Phase…
Isofol’s Board of Directors appoints Roger Tell as acting CEO of the company
Gothenburg, Sweden, June 22, 2023 – Isofol Medical AB (publ) announces today that its Board of Directors has decided to appoint Roger Tell as…
INVESTORS – Latest reports and presentations
FOLLOW US
Stay updated on the latest news by
following Isofol on Linkedin.
